BeyondSpring Inc. announced on May 28, 2025, that it would present interim Phase 2 data from its 303 Study at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The presentation is scheduled for May 31, 2025, in Chicago, IL.
The 303 Study is an investigator-initiated trial evaluating a triple combination of Plinabulin, pembrolizumab, and docetaxel in second- and third-line non-small cell lung cancer (NSCLC) patients. These patients have progressed on prior PD-1/L1 inhibitors, representing a population with significant unmet medical needs.
The upcoming presentation at ASCO, a prominent oncology conference, highlights the ongoing clinical development of Plinabulin and its potential role in re-sensitizing tumors to checkpoint inhibitors. The study is supported by Merck's Investigator Studies Program.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.